Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimasertib - Day One Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Pimasertib - Day One Biopharmaceuticals

Alternative Names: AS-703026; EMD-1036239; MSC 1936369; MSC 1936369B; MSC1936369A

Latest Information Update: 21 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Day One Biopharmaceuticals; Merck Serono; Sanofi
  • Class Amides; Aminopyridines; Antineoplastics; Iodobenzenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Haematological malignancies; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 30 Jul 2024 Discontinued - Phase-I/II for Solid tumours (Combination therapy, In adolescents, In the elderly, Recurrent, Second-line therapy or greater, In adults) in USA, South Korea, Spain, Belgium, Belgium, Canada, Australia, France (PO)
  • 09 May 2024 Day One Biopharmaceuticals has patent covering composition of matter and methods of use of pimasertib issued in USA and granted in Argentina, Austria, Australia, Belgium, Bulgaria, Brazil, Canada, Switzerland, China, Cyprus, Czech Republic, Germany, Denmark, Eurasia, Estonia, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Hungary, Ireland, Israel, India, Iceland, Italy, Japan, Korea, Lithuania, Luxembourg, Latvia, Monaco, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Sweden, Singapore, Slovenia, Slovakia, Turkey, Ukraine, and South Africa
  • 09 May 2024 Day One Biopharmaceuticals has patent directed to the solid state form of pimasertib issued in USA and granted in Austria, Australia, Belgium, Canada, Switzerland, Czech Republic, Germany, Denmark, Eurasia, Spain, France, United Kingdom, Italy, Japan, Luxembourg, Mexico, Netherlands, Poland, Portugal, Russian Federation, Sweden, Singapore, Taiwan, and South Africa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top